M
MBX
MBX Biosciences Inc
31.47
-0.43-1.35%After Hours: 31.47 0.00 0.00%17:40 05/29 EDT
OPEN/PREV CLOSE30.29/30.65
TODAY RANGE29.57-31.35
VOL175.23K
MARKET CAP1.46B
52 WEEK RANGE9.43-45.85
AVG VOL (3M)567.32K
% TURNOVER0.37%
TURNOVER--
P/E (TTM)-13.8445
% RANGE5.81%
EPS(TTM)-2.2081
P/E(FORWARD)-11.0361
P/B3.322
BVPS9.20
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.10B
SHARES OUTSTANDING47.60M
NEXT EARNINGS08/05-08/10
FREE FLOAT36.02M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
The Motley Fool·5d ago
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run
Simply Wall St·05/17 20:25
MBX Biosciences (MBX) Is Down 20.8% After Wider Loss, Obesity Data And New CCO - Has The Bull Case Changed?
TipRanks·05/16 14:36
LifeSci Capital Remains a Buy on MBX Biosciences, Inc. (MBX)
Simply Wall St·05/14 09:42
MBX Biosciences Advances Obesity And PBH Pipeline As Shares Surge
TipRanks·05/12 16:23
MBX Biosciences price target raised to $56 from $50 at Stifel
Dow Jones·05/12 14:00
MBX Biosciences Is Maintained at Overweight by Barclays
Benzinga·05/12 13:51
Barclays Maintains Overweight on MBX Biosciences, Raises Price Target to $70
Dow Jones·05/12 12:46
MBX Biosciences Is Maintained at Market Outperform by Citizens
TipRanks·05/12 12:11
MBX Biosciences, Inc. (MBX) Receives a Buy from Oppenheimer
TipRanks·05/12 11:27
Stifel Nicolaus Sticks to Its Buy Rating for MBX Biosciences, Inc. (MBX)
Reuters·05/12 11:11
MBX BIOSCIENCES INC <MBX.O>: BARCLAYS RAISES TARGET PRICE TO $70 FROM $66
Reuters·05/12 10:46
MBX BIOSCIENCES INC <MBX.O>: STIFEL RAISES TARGET PRICE TO $56 FROM $50
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.